NASDAQ:KURA

Kura Oncology (KURA) Stock Forecast, Price & News

$13.20

-0.30 (-2.22%)

(As of 06/2/2023 ET)

Compare

Today's Range: $13.14
▼
$13.68
50-Day Range: $9.62
▼
$13.99
52-Week Range: $9.49
▼
$19.93

Volume: 621,132 shs
Average Volume: 646,178 shs
Market Capitalization: $903.41 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $29.71

Kura Oncology MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 125.1% Upside
$29.71 Price Target
Short Interest: Bearish
12.42% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.76
Upright™ Environmental Score
News Sentiment: 0.98
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.33) to ($2.22) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

593rd out of 983 stocks

Pharmaceutical Preparations Industry

295th out of 486 stocks

3.5

Analyst's Opinion

Consensus Rating
Kura Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $29.71, Kura Oncology has a forecasted upside of 125.1% from its current price of $13.20.
Amount of Analyst Coverage
Kura Oncology has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
12.42% of the float of Kura Oncology has been sold short.
Short Interest Ratio / Days to Cover
Kura Oncology has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.
Change versus previous month
Short interest in Kura Oncology has recently decreased by 0.38%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Kura Oncology does not currently pay a dividend.
Dividend Growth
Kura Oncology does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Kura Oncology has received a 73.98% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Kura Oncology is -0.76.

2.2

News and Social Media Coverage

News Sentiment
Kura Oncology has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Kura Oncology this week, compared to 3 articles on an average week.
Search Interest
Only 1 people have searched for KURA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Kura Oncology insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.40% of the stock of Kura Oncology is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Kura Oncology are expected to grow in the coming year, from ($2.33) to ($2.22) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Kura Oncology is -6.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Kura Oncology is -6.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Kura Oncology has a P/B Ratio of 2.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Kura Oncology (NASDAQ:KURA) Stock

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Receive KURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter.

KURA Stock News Headlines

May 30, 2023 | finance.yahoo.com

Kura Oncology Announces Late-Breaking Abstract Accepted for Oral Presentation at the 2023 European Hematology Association (EHA) Congress

May 29, 2023 | markets.businessinsider.com

Kura Oncology (KURA) Gets a Buy from Stifel Nicolaus

June 2, 2023 | Legacy Research (Affiliate) (Ad)

Sell Every Stock, Except ONE (Ticker Revealed)

We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.

May 19, 2023 | msn.com

Unusual Call Option Trade in Kura Oncology (KURA) Worth $317.50K

May 19, 2023 | americanbankingnews.com

Kura Oncology (NASDAQ:KURA) Earns Buy Rating from Analysts at BTIG Research

May 18, 2023 | seekingalpha.com

Kura Oncology (KURA) Investor Presentation - Slideshow

May 18, 2023 | americanbankingnews.com

StockNews.com Initiates Coverage on Kura Oncology (NASDAQ:KURA)

May 18, 2023 | americanbankingnews.com

Kura Oncology (NASDAQ:KURA) Shares Gap Down to $12.66

June 2, 2023 | Legacy Research (Affiliate) (Ad)

Sell Every Stock, Except ONE (Ticker Revealed)

May 17, 2023 | msn.com

BTIG Initiates Coverage of Kura Oncology (KURA) with Buy Recommendation

May 17, 2023 | markets.businessinsider.com

Stifel Nicolaus Sticks to Their Buy Rating for Kura Oncology (KURA)

May 16, 2023 | americanbankingnews.com

Q2 2023 EPS Estimates for Kura Oncology, Inc. (NASDAQ:KURA) Raised by Analyst

May 16, 2023 | americanbankingnews.com

Q2 2023 EPS Estimates for Kura Oncology, Inc. Cut by Analyst (NASDAQ:KURA)

May 16, 2023 | americanbankingnews.com

Q2 2023 Earnings Forecast for Kura Oncology, Inc. (NASDAQ:KURA) Issued By HC Wainwright

May 14, 2023 | americanbankingnews.com

Stifel Nicolaus Lowers Kura Oncology (NASDAQ:KURA) Price Target to $24.00

May 13, 2023 | finance.yahoo.com

Kura Oncology, Inc. (NASDAQ:KURA) Q1 2023 Earnings Call Transcript

May 13, 2023 | americanbankingnews.com

Kura Oncology, Inc. (NASDAQ:KURA) to Post FY2025 Earnings of $4.86 Per Share, Brookline Capital Management Forecasts

May 13, 2023 | americanbankingnews.com

Brokerages Set Kura Oncology, Inc. (NASDAQ:KURA) PT at $29.60

May 12, 2023 | markets.businessinsider.com

JMP Securities Remains a Buy on Kura Oncology (KURA)

May 11, 2023 | msn.com

Credit Suisse Reiterates Kura Oncology (KURA) Outperform Recommendation

May 11, 2023 | msn.com

HC Wainwright & Co. Reiterates Kura Oncology (KURA) Buy Recommendation

May 11, 2023 | markets.businessinsider.com

SVB Securities Reaffirms Their Buy Rating on Zai Lab (ZLAB)

May 11, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Their Buy Rating for Kura Oncology (KURA)

May 11, 2023 | finance.yahoo.com

Q1 2023 Kura Oncology Inc Earnings Call

May 10, 2023 | msn.com

Kura Oncology: Q1 Earnings Insights

May 10, 2023 | finance.yahoo.com

Kura Oncology Reports First Quarter 2023 Financial Results

May 10, 2023 | finance.yahoo.com

Kura Oncology Reports First Quarter 2023 Financial Results

See More Headlines

KURA Price History

30 days | 90 days | 365 days | Advanced Chart

KURA Company Calendar

Last Earnings: 5/10/2023
Today: 6/02/2023
Next Earnings (Estimated): 8/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:KURA
CUSIP: N/A
CIK: 1422143
Web: www.kuraoncology.com
Phone: (858) 500-8800
Fax: N/A
Employees: 121
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $29.71
High Stock Price Forecast: $40.00
Low Stock Price Forecast: $22.00
Forecasted Upside/Downside: +124.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.04)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-135,840,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -32.64%
Return on Assets: -30.52%

Debt

Debt-to-Equity Ratio: 0.02
Current Ratio: 21.65
Quick Ratio: 21.65

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.77 per share
Price / Book: 2.29

Miscellaneous

Outstanding Shares: 68,440,000
Free Float: 64,743,000
Market Cap: $906.15 million
Optionable: Optionable
Beta: 0.86

Key Executives

Troy E. Wilson
Chairman, President, CEO & Chief Financial Officer

Kathleen Ford
Chief Operating Officer

Stephen Dale
Chief Medical Officer

Mollie Leoni
Senior Vice President-Clinical Development

Thomas Doyle
Chief Accounting Officer & Senior VP-Finance

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KURA Stock - Frequently Asked Questions

Should I buy or sell Kura Oncology stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KURA shares.
View KURA analyst ratings or view top-rated stocks.
What is Kura Oncology's stock price forecast for 2023?: 7 brokerages have issued 12-month price objectives for Kura Oncology's stock. Their KURA share price forecasts range from $22.00 to $40.00. On average, they predict the company's stock price to reach $29.71 in the next twelve months. This suggests a possible upside of 125.1% from the stock's current price.
View analysts price targets for KURA or view top-rated stocks among Wall Street analysts.
How have KURA shares performed in 2023?: Kura Oncology's stock was trading at $12.41 on January 1st, 2023. Since then, KURA stock has increased by 6.4% and is now trading at $13.20.
View the best growth stocks for 2023 here.
When is Kura Oncology's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our KURA earnings forecast.
How were Kura Oncology's earnings last quarter?: Kura Oncology, Inc. (NASDAQ:KURA) issued its quarterly earnings results on Wednesday, May, 10th. The company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.04.
What ETFs hold Kura Oncology's stock?: ETFs with the largest weight of Kura Oncology (NASDAQ:KURA) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), iShares Biotechnology ETF (IBB) and Invesco Nasdaq Biotechnology ETF (IBBQ).

What other stocks do shareholders of Kura Oncology own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD).
What is Kura Oncology's stock symbol?: Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."
Who are Kura Oncology's major shareholders?: Kura Oncology's stock is owned by a variety of retail and institutional investors. Top institutional investors include BVF Inc. IL (9.84%), Suvretta Capital Management LLC (9.60%), BlackRock Inc. (7.85%), State Street Corp (5.61%), Dimensional Fund Advisors LP (2.68%) and Geode Capital Management LLC (1.88%). Insiders that own company stock include Kathleen Ford, Kirsten Flowers, Marc Grasso, Thomas James Doyle and Troy Edward Wilson.
View institutional ownership trends.
How do I buy shares of Kura Oncology?: Shares of KURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Kura Oncology's stock price today?: One share of KURA stock can currently be purchased for approximately $13.20.
How much money does Kura Oncology make?: Kura Oncology (NASDAQ:KURA) has a market capitalization of $903.41 million. The company earns $-135,840,000.00 in net income (profit) each year or ($2.04) on an earnings per share basis.
How many employees does Kura Oncology have?: The company employs 121 workers across the globe.
How can I contact Kura Oncology?: Kura Oncology's mailing address is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. The official website for the company is www.kuraoncology.com. The company can be reached via phone at (858) 500-8800 or via email at ir@kuraoncology.com.

This page (NASDAQ:KURA) was last updated on 6/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Kura Oncology (KURA) Stock Forecast, Price & News

Kura Oncology MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Kura Oncology (NASDAQ:KURA) Stock

KURA Stock News Headlines

KURA Price History

KURA Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

KURA Stock - Frequently Asked Questions

Overall MarketRank^™